L01AX04 • dacarbazine • Antineoplastic and immunomodulating agents | Alkylating agents | Other alkylating agents
Dacarbazine is a chemotherapy medication used for the treatment of malignant melanoma, Hodgkin's disease, and other types of cancer. It acts as an alkylating agent, interfering with DNA synthesis and inhibiting cell division.
The medication is administered via intravenous infusion, with the dose determined by the physician based on the type of cancer and the patient's overall condition. Common side effects include nausea, vomiting, fatigue, and bone marrow suppression.
Dacarbazine is contraindicated in patients with hypersensitivity to the active substance or any of its excipients. It should also be used with caution in patients with hepatic or renal impairment.
This medication is an important option in cancer treatment, helping to reduce tumor size and improve the prognosis of affected patients.
Substance: dacarbazine
Date of last drug list: 01-12-2017
Commercial code: W63917001
Concentration: 1000mg
Pharmaceutical form: powder infusion solution
Quantity: 1
Product type: generic
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).
Manufacturer: LIPOMED GMBH - GERMANIA
Holder: LIPOMED GMBH - GERMANIA
Number: 10126/2017/01
Shelf life: 3 years